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Figure 1 shows the 3D-vector motion amplitudes for the twenty 
patients. A median initial tumor motion was observed of 1.3 mm 
(range: 0.0 – 7.4 mm). Four patients showed a motion amplitude 
beyond 5 mm during the course of treatment. 7 out of 20 patients 
showed motion variation of more than 3 mm compared to the motion 
measured in week 0. Figure 2 visualizes two coronal fusion views of 
patients with smaller and larger motion variation. The median initial 
GTV volume was 28.7 cm3 (range 1.0 – 430.0 cm3). During treatment 
GTV volumes of 16 out of 19 patients shrunk with a median decrease 
of 39% (range: 10.8%- 63.7%), and a median absolute volume 
change of 8.3 cm3 (range: 0.5-105.9 cm3). 
Figure 3 shows that motion amplitudes extracted from weekly 4DCTs 
were not predictive for motion amplitudes extracted from daily 
4DCBCTs for patients number 14. This patient showed larger motion 
amplitudes with a maximum weekly variation of 6.8 mm. Motion 
amplitudes measured by 4DCBCTs showed a daily variation up to 
11.2 mm.  
We are currently extending the presented data for a weekly motion 
analysis in 40, and  a daily motion analysis in 10 lung patient cases. 
For pencil beam scanning intensity modulated proton therapy (PBS-
IMPT) moving targets remain challenging. The time structure of PBS-
IMPT makes the treatment of moving tumours challenging due to the 
interplay effect. Even when using motion mitigation strategies, one 
needs to be aware of motion variations. Therefore, we investigated 
weekly and daily inter-fraction motion variations to define the most 
optimal motion monitoring protocol for PBS-IMPT treatments of non-
small-cell lung cancer ([N]SCLC) patients. 
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To define the most optimal motion monitoring protocol for 
PBS-IMPT treatments of (N)SCLC cancer patients by 
investigating weekly and daily motion variations. 
CONCLUSION 
For a considerable part of the patients, the motion measured in week 0 based on weekly repeat 4DCT imaging was not predictive 
for motion in the following weeks. Daily motion measured by 4DCBCT imaging for one patient suggests that weekly measured 
4DCT motion is not predictive for the daily motion in between the weekly 4DCTs. This indicates that breathing motion differs from 
day to day and daily 4D-imaging is therefore needed to assure safe PBS-PT treatments for lung cancer patients.  
l.a.den.otter@umcg.nl 
MATERIALS & METHODS 
For 20 (N)SCLC patients (12 male, 8 female, age: 47-89, stage II-IV) 
4DCT imaging was performed during pre-treatment simulation (week 
0). In addition, weekly 4DCT imaging was performed during the 
treatment course of five weeks (week 1-5). This is to monitor 
anatomical changes and differences in motion. Gross tumor volumes 
(GTVs) were delineated on the maximum inspiration and expiration 
4DCT phases. For each weekly delineated GTV,  the centroid was 
calculated and centroid 3D-vector translations were evaluated 
accordingly.  
For one patient, daily 3D-vector centroid 4DCBCT motion was 
evaluated additionally. This was also done by delineating the GTV on 
the maximum inspiration and expiration 4DCBCT phases, calculating 
the centroid positions and evaluating the centroid 3D-vector 
translations. 
 
Figure 1: GTV-motion variations for 20 (N)SCLC patients extracted from 
weekly 4DCTs. 
Figure 3: GTV-motion variations for patient 14 extracted from weekly 
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Figure 2: Coronal fusion views of patient’s GTVs at maximum inspiration 
and expiration phases. One patient showed little tumor motion variation 
and the second patient showed larger motion variation.  
